Showing 581 - 600 results of 2,530 for search '"vaccines"', query time: 0.06s Refine Results
  1. 581

    Development of Delivery Systems Enhances the Potency of Cell-Based HIV-1 Therapeutic Vaccine Candidates by Amin Hadi, Abbas Rastgoo, Maryam Eskandarian, Nooshin Haghighipour, Azam Bolhassani

    Published 2021-01-01
    “…Among different vaccination strategies, cell-based vaccines could achieve in clinical trials. …”
    Get full text
    Article
  2. 582
  3. 583
  4. 584
  5. 585

    Lymphadenitis as a Rare Side Effect of H1N1 Vaccine in a Child by Zuhal Gundogdu, Mualla Seyhogullari

    Published 2010-01-01
    “…We present a 5-year-old boy who had the complaint of swelling and pain on the right vaccine shot and right axillary areas. The right axillary area was diagnosed as reactive lymphadenitis, which we believe is a rare local side effect of the swine flu vaccine. …”
    Get full text
    Article
  6. 586
  7. 587

    Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

    Published 2023-01-01
    “…We have reported that a single fraction of 12 Gy EBRT combined with intratumoral anti-GD2 hu14.18-IL2 immunocytokine (IC) generates an effective in situ vaccine (ISV) against GD2-positive murine tumors. …”
    Get full text
    Article
  8. 588
  9. 589

    How Many Individuals with Asthma Need to Be Vaccinated to Prevent One Case of Invasive Pneumococcal Disease? by Julie M Okapuu, Estelle Chétrit, Brigitte Lefebvre, Caroline Quach

    Published 2014-01-01
    “…BACKGROUND: The American Advisory Committee on Immunization Practices recommended the inclusion of adults with asthma in the high-risk category for pneumococcal vaccination based on a twofold increase in risk of invasive pneumococcal disease (IPD).…”
    Get full text
    Article
  10. 590
  11. 591

    Antibody Responses and the Vaccine Efficacy of Recombinant Glycosyltransferase and Nicastrin Against <i>Schistosoma japonicum</i> by Bowen Dong, Haoran Zhong, Danlin Zhu, Luobin Wu, Jinming Wang, Hao Li, Yamei Jin

    Published 2025-01-01
    “…While praziquantel remains the primary treatment, concerns about drug resistance highlight the urgent need for new drugs and effective vaccines to achieve sustainable control. Previous proteomic studies from our group revealed that the expression of <i>Schistosoma japonicum</i> glycosyltransferase and nicastrin as proteins was higher in single-sex males than mated males, suggesting their critical roles in parasite reproduction and their potential as vaccine candidates. …”
    Get full text
    Article
  12. 592
  13. 593
  14. 594

    Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus? by Neeraj Narula, Deborah LR Yamamura, John K Marshall

    Published 2010-01-01
    “…Studies in other immunosuppressed populations have also demonstrated the safety of inactivated vaccines. The present article reviews the literature regarding the safety and efficacy of influenza vaccination in IBD patients receiving immunosuppressive therapy.…”
    Get full text
    Article
  15. 595

    Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus by RT Ross, MR Dawood, Mary Cheang, Lindsay E Nicolle

    Published 1996-01-01
    “…OBJECTIVE: To determine the safety and effectiveness of live attenuated varicella zoster virus (VZV) vaccine (OKA/Merck) on 50 patients with chronic progressive multiple sclerosis (MS), based on the hypothesis that VZV might be the antigen or antigen mimic of MS plus the fact that repeated high antigen doses have produced ‘antigen paralysis’ in experimental allergic encephalomyelitis mice.…”
    Get full text
    Article
  16. 596
  17. 597
  18. 598
  19. 599
  20. 600

    Efficacy of bivalent vaccine against black body syndrome (BBS) of barramundi Lates calcalifer B. by Anis Nugrahawati, Sri Nuryati, Sukenda Sukenda, Rahman Rahman, Margie Brite, Tiya Widi Aditya

    Published 2019-06-01
    “…The bacteria used in the bivalent vaccine were Pseudomonas stutzeri and Vibrio harveyi in a ratio of 50:50. …”
    Get full text
    Article